Clinical Research Studies in Pickup Family Neurosciences Institute
Participation in research and clinical investigation is an important commitment of Pickup Family Neurosciences Institute in its mission to provide patients access to leading-edge management and treatment for neurological disorders.
Hoag’s sub-specialized team of neuroscientists are actively involved in research to discover new therapies, drugs and other medical advancements to better the lives of patients suffering from neurological conditions. Pickup Family Neurosciences Institute is currently accepting patients to participate in a number of clinical research trials.
We offer a variety of clinical research studies in the following neurosciences therapeutic areas:
Brain Cancer
Epilepsy
- (160-20) Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)
(Study appropriate for patients with intractable mesial temporal lobe epilepsy)
Memory and Cognitive Disorders
- (101-20) AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid
(Phase 3 study, appropriate for patients with preclinical Alzheimer’s disease and elevated amyloid and patients with early preclinical Alzheimer’s disease and intermediate amyloid.) - (181-21) A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 76-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF TWO DOSES OF SIMUFILAM IN SUBJECTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE
- (181-23) An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 mg Tablets in Participants With Mild to Moderate Alzheimer’s Disease
- (103-22) A Phase I, Randomized, Double-Blind Study to Evaluate Safety and Tolerability of Amyloid-β Vaccine, AV-1959D, in Patients with Early Alzheimer’s Disease” with The Institute for Molecular Imaging.
- (171-22) A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer’s Disease (ENVISION)
- (114-23) A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)” with EIP Pharma, Inc.
- (204-22) A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)
- (190-21) Ph 1, Open-Label Safety Study of Escalating Doses of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous ADSCs in Participants With Mild-Moderate AD Whose Treatment is Not Addressed Adequately by Available Therapy
Stroke
- (157-20) Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE) (Phase 3 clinical trial, appropriate for patients with intracerebral hemorrhage.)
- (254-22) A Study to Test Asundexian to Prevent a Clot-related Stroke in Participants After an Acute Ischemic Stroke or High-risk TIA/Mini-stroke (Transient Ischemic Attack) (OCEANIC-STROKE)
Other
- (113-22) A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)
- (190-22) Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis
Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.
To learn more about available clinical trials, please contact us at 949-764-4577 or clinicalresearch@hoag.org.